Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

Multiple Sclerosis, Relapsing Clinical Trial

Official title: An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

Status Active, not recruiting

Clinical Trial Summary

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing
• Sclerosis

• NCT number: NCT04377555
• Study type: Interventional
• Source: Genentech, Inc.
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: July 30, 2020
• Completion date: December 29, 2025